Format

Send to

Choose Destination
Arch Dermatol. 2002 Jan;138(1):29-32.

Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples.

Author information

1
Department of Dermatology, Instituto Português Oncologia, 4200 Porto, Portugal. osvaldo.correia@netc.pt

Abstract

BACKGROUND:

Toxic epidermal necrolysis (TEN) is a rare but severe adverse drug disease, characterized by extensive skin and mucosal detachment with participation of different immunoinflammatory pathways, in particular with early participation of activated CD8+ T lymphocytes.

OBJECTIVE:

To further study the potential role of T lymphocytes in the early phase of keratinocyte necrosis.

DESIGN:

Prospective study.

SETTING:

University hospitals.

PATIENTS:

Thirteen patients with clinical and histopathologic criteria of TEN and 6 patients with second-degree burns.

MAIN OUTCOME MEASURES:

Measurement of soluble interleukin (IL) 2 receptor (sIL-2R) and IL-1alpha in serum samples and fluid of recent blisters.

RESULTS:

In the blister fluid of patients with TEN, we found significantly higher levels of sIL-2R than in patients with burns, whereas IL-1alpha levels were higher in the blister fluid of burned patients. No significant differences were found in serum samples of patients with TEN and burns, in either sIL-2R or IL-1alpha. In TEN we also found significantly higher levels of sIL-2R in the blister fluid compared with serum samples, pointing to a predominantly local production contrasting with the low concentration of sIL-2R in the blister fluid of burned patients.

CONCLUSIONS:

Our findings of elevated sIL-2R levels in blister fluid of patients with TEN are probably related to a local down-regulation of an immunologically mediated cytotoxic reaction and further support the involvement of activated T lymphocytes in the early blisters of TEN.

PMID:
11790164
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center